secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2023-12-13T23:59:59+00:00
Accession:  0001193125-23-293959
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports Phase 1 data for BA3071: confirmed responses in solid tumors, safe profile, Phase 2 initiated
--------------------------------------------------------------------------------

- Phase 1 dose-escalation of BA3071 (CAB-CTLA-4) in 18 PD-1-failure patients: 2 confirmed responses (1 CR stage IV cervical, 1 PR stage IV gastro-esophageal), 9 stable disease.
- No grade 4 treatment-emergent adverse events; two grade 3 immune-related AEs. Maximum tolerated dose not reached; DLT at 700 mg.
- Durable disease control: uveal melanoma (>12 cycles), cutaneous melanoma (>14, >17 cycles), SCLC (>22 cycles).
- Phase 2 monotherapy and in combination with PD-1 inhibitor is now underway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/0001193125-23-293959-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000119312523293959/d35885d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-293959

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer